New cell type developed for possible treatment of Alzheimer's and other brain diseases
Advertisement
UC Irvine researchers have created a new stem cell-derived cell type with unique promise for treating neurodegenerative diseases such as Alzheimer's.
Dr. Edwin Monuki of UCI's Sue & Bill Gross Stem Cell Research Center, developmental & cell biology graduate student Momoko Watanabe and colleagues developed these cells – called choroid plexus epithelial cells – from existing mouse and human embryonic stem cell lines.
CPECs are critical for proper functioning of the choroid plexus, the tissue in the brain that produces cerebrospinal fluid. Among their various roles, CPECs make CSF and remove metabolic waste and foreign substances from the fluid and brain.
In neurodegenerative diseases, the choroid plexus and CPECs age prematurely, resulting in reduced CSF formation and decreased ability to flush out such debris as the plaque-forming proteins that are a hallmark of Alzheimer's. Transplant studies have provided proof of concept for CPEC-based therapies. However, such therapies have been hindered by the inability to expand or generate CPECs in culture.
"Our method is promising, because for the first time we can use stem cells to create large amounts of these epithelial cells, which could be utilized in different ways to treat neurodegenerative diseases," said Monuki, an associate professor of pathology & laboratory medicine and developmental & cell biology at UCI.
The study appears in The Journal of Neuroscience.
To create the new cells, Monuki and his colleagues coaxed embryonic stem cells to differentiate into immature neural stem cells. They then developed the immature cells into CPECs capable of being delivered to a patient's choroid plexus.
These cells could be part of neurodegenerative disease treatments in at least three ways, Monuki said. First, they're able to increase the production of CSF to help flush out plaque-causing proteins from brain tissue and limit disease progression. Second, CPEC "superpumps" could be designed to transport high levels of therapeutic compounds to the CSF, brain and spinal cord. Third, these cells can be used to screen and optimize drugs that improve choroid plexus function.
Monuki said the next steps are to develop an effective drug screening system and to conduct proof-of-concept studies to see how these CPECs affect the brain in mouse models of Huntington's, Alzheimer's and pediatric diseases.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
AMRI Announces Strategic Contract with Knopp Biosciences
Kinaxo Starts Collaboration with Roche in the Field of Phosphoproteomics
Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer
New tool for studying magnetic, self-propelled bacteria that resemble compass needles
New Biomedical Sciences Executive Committee Established to Lead Phase 2 of Singapore's Biomedical Sciences Initiative
EHEC O104:H4 outbreak event in Germany clarified: sprouts of fenugreek seeds imported from Egypt as underlying cause
Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model - New study shows GM-CSF reduces AD pathology and eliminates memory loss
Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures
Chemokine Therapeutics achieves critical milestone with the start of a phase Ib/II human clinical trial in cancer
Positive Phase II preliminary results of Validive for the prevention of Severe Oral Mucositis in Head and Neck cancer patients - Improved oral mucositis related symptoms and decreased adverse events related to radiotherapy
